# OnCo record mesothelioma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/mesothelioma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "mesothelioma" ;
  schema:name "Mesothelioma"@en ;
  schema:description "An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."@en ;
  schema:url <https://onco.cc/cancers/mesothelioma/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mesothelioma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1077603> ;
  schema:citation <https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq> ;
  onco:tag "thoracic" ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/ttfields/>, <https://onco.cc/technologies/synthetic-lethality-approaches/>, <https://onco.cc/technologies/pleurectomy-decortication/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/mesothelin/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/talc-sclerosant/> ;
  onco:companies <https://onco.cc/companies/orion-orion-pharma/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/novocure/>, <https://onco.cc/companies/boehringer-ingelheim/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/the-christie/>, <https://onco.cc/institutions/nki/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/epithelioid-vs-sarcomatoid/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/nct06097728/> ;
  onco:pipeline <https://onco.cc/technologies/synthetic-lethality-approaches/>, <https://onco.cc/drugs/eb-mf-car-nk-01/>, <https://onco.cc/drugs/anetumab-ravtansine/>, <https://onco.cc/ideas/idea-adc-for-mesothelioma/>, <https://onco.cc/trials/anetumab-vs-vinorelbine-mpm/>, <https://onco.cc/trials/nci-anetumab-pembrolizumab-mpm/>, <https://onco.cc/trials/ucl-proton-hemithoracic-mpm/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/ideas/idea-mtap-prmt5-mesothelioma/>, <https://onco.cc/ideas/idea-mesothelin-car-t-regional/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/armored-car/>, <https://onco.cc/targets/mesothelin/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/ttfields/>, <https://onco.cc/pairings/histology-directs-first-line-meso/>, <https://onco.cc/technologies/fapi-pet/> ;
  onco:standardOfCare <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/checkmate-743/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-483/>, <https://onco.cc/pairings/histology-directs-first-line-meso/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-483/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/trials/maps/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/technologies/ttfields/>, <https://onco.cc/trials/stellar/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/technologies/pleurectomy-decortication/>, <https://onco.cc/trials/mars-2/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/hipec/> .